Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 13,302 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 13,302 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $80.00, for a total transaction of $1,064,160.00. Following the transaction, the chief financial officer now owns 142,204 shares of the company’s stock, valued at approximately $11,376,320. The trade was a 8.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total value of $227,979.00.

Insmed Stock Down 1.2 %

Shares of NASDAQ INSM opened at $78.67 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm’s 50-day moving average is $73.23 and its two-hundred day moving average is $73.20. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $82.04. The company has a market capitalization of $14.07 billion, a PE ratio of -14.17 and a beta of 1.11.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently bought and sold shares of INSM. Truist Financial Corp acquired a new position in shares of Insmed in the second quarter worth $413,000. GAMMA Investing LLC increased its position in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the last quarter. Creative Planning raised its stake in Insmed by 31.2% in the 3rd quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock valued at $3,279,000 after purchasing an additional 10,668 shares during the last quarter. Finally, V Square Quantitative Management LLC purchased a new position in Insmed in the 3rd quarter valued at about $30,000.

Wall Street Analyst Weigh In

INSM has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Guggenheim increased their price objective on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.60.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.